Skip to main content
Signal8

4D Molecular Therapeutics, Inc. (FDMT)

Sector: Biological Products, (No Diagnostic Substances)

Industry: Biotechnology

4D Molecular Therapeutics, Inc. logo

4D Molecular Therapeutics, Inc.

NASDAQ:FDMTHealthcare
Pre+0.00%$12.25
Close$12.25+8.89%AH$12.25+0.00%vs close
Mkt Cap$676.74M
Float53.34M
O/S55.24M
Inst Own-
SI21.6%
EarningsNov 11 · in 2d
Dilution
4D Molecular Therapeutics, Inc. logoNASDAQ:FDMTPre$12.25+0.00%
Historical Data
DateOpenHighLowCloseVolume
Nov 6, 202611.4612.5711.2812.25993,260
Nov 5, 202612.1112.1111.1611.251,598,598
Nov 4, 202612.3612.4411.5112.28764,668
Nov 3, 202611.5212.0911.4611.95740,405
Nov 2, 202611.8812.0611.1611.37734,784
Oct 30, 202612.4912.8811.7311.90683,494
Oct 29, 202613.0013.4612.5712.78848,927
Oct 28, 202611.8912.9611.7312.931,189,801
Oct 27, 202610.9611.9910.7511.961,134,654
Oct 26, 202610.7411.2910.6211.031,084,579
Oct 23, 202611.7411.7510.6810.80996,140
Oct 22, 202612.6013.1211.6811.851,354,686
Oct 21, 202613.1213.4512.6112.622,019,208
Oct 20, 202612.2913.3912.2913.10725,372
Oct 19, 202612.3612.6812.2112.29855,680
Oct 16, 202612.8412.8412.0012.14794,535
Oct 15, 202612.3013.0112.0412.87787,614
Oct 14, 202612.1812.5811.9912.20632,964
Oct 13, 202612.9112.9112.2512.36991,721
Oct 12, 202613.3013.4712.8613.00835,835
Analyst Coverage
Analyst Coverage
ConsensusBuy
Price Target (median, last 90d)
$26.00+112.2%
Low $20High $32
Ratings Distribution
BUY
11
HOLD
2
SELL
1
TOTAL14
Insider Trades
InsiderTypeShares
Bizily Scott profile photoBizily ScottSale1.6K
Bizily Scott profile photoBizily ScottOption Exercise1.6K
Bizily Scott profile photoBizily ScottOption Exercise1.6K
Kirn David profile photoKirn DavidSale58.1K
Kirn David profile photoKirn DavidSale272
Bizily Scott profile photoBizily ScottSale1.6K
Shareholders
-
Institutionalⓘ
(163)
1.5%
Insiderⓘ
(4)
8.4%
5%+ Owners
(1)
-
Unattributed (incl. retail)ⓘ
Insider1.5%
5%+ Beneficial8.4%
Sources: 13F, Form 4, 13D/13GO/S: 55.2M · checked 9 Nov 2026 · market-data provider
Insiders & Institutional Holders

Insiders

Top institutional holders

About

4D Molecular Therapeutics, Inc. is a clinical-stage gene therapy company that engineers therapeutic agents by leveraging its proprietary adeno-associated virus (AAV) vector technology.

The company's developmental efforts are concentrated across a trio of therapeutic fields: ophthalmology (eye conditions), cardiology (heart ailments), and pulmonology (respiratory disorders). Within its active pipeline, three specific product candidates have advanced into clinical trial phases, all currently undergoing Phase 1/2 clinical assessment: 4D-125 is being evaluated for the treatment of X-linked retinitis pigmentosa. 4D-110 targets choroideremia. 4D-310 is focused on addressing Fabry disease. Beyond these, two Investigational New Drug (IND) candidates are in development: 4D-150, aimed at combating wet age-related macular degeneration, and 4D-710, designed to tackle cystic fibrosis lung disease. To advance its mission, 4D Molecular Therapeutics, Inc. actively engages in research and development partnerships with entities such as uniQure, CRF, Roche, and CFF.

The firm commenced operations in 2013 and maintains its headquarters in Emeryville, California.

Key Metrics
Market Cap$676.74M
Enterprise Value--
P/E Ratio--
Est. Net Cash/Share--
Institutional Ownership-

13F filers report 58.32M shares, more than the 55.24M outstanding, so no percentage is shown. 13F reports lag by a quarter and shares lent to short sellers can be counted twice.

SectorHealthcare
IndustryBiotechnology
ExchangeNASDAQ
CountryUSUS
IPO DateDec 11, 2020
Shares Outstanding55.24M
Authorized Shares
Float53.34M
52-Week Range
$6.96$16.93
$12.25(53rd percentile)
Volume
Average Daily Volume988.35K
993.26K today vs 988.35K avg(+0%)

30d Avg

988.35K

60d Avg

1.04M

90d Avg

1.06M

Earnings
Dividend History
No dividend history available
Compliance Status
Loading compliance data...